Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients

Makoto Nagahara, Koshi Mimori, Akemi Kataoka, Hideshi Ishii, Fumiaki Tanaka, Tsuyoshi Nakagawa, Takanobu Sato, Shinji Ono, Kenichi Sugihara, Masaki Mori

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: CD47 plays a variety of roles in intercellular signaling. Herein, we focused on the clinicopathologic significance of CD47 expression in human breast cancer. Our data suggest that the correlation between CD47 and signal regulatory protein α (SIRPA) expression may play a key role in the progression of breast cancer. Experimental Design: Quantitative real-time PCR was used to evaluate CD47 mRNA and SIRPA mRNA expression in bone marrow and in peripheral blood from 738 cases of breast cancer. Results: In patients with high levels of CD47 expression in the bone marrow, survival was significantly poorer compared with patients with low levels of CD47 expression [disease-free survival (DFS), P = 0.0035; overall survival (OS), P = 0.015]. Furthermore, high CD47 expression group in a multivariate analysis showed significance as an independent variable for poorer prognosis in DFS (P = 0.024). In the peripheral blood, however, high CD47 expression in patients was not an independent and significant prognostic factor for DFS and OS in a multivariate analysis. CD47 expression was strongly correlated with SIRPA expression in both the bone marrow (P < 0.0001) and peripheral blood (P < 0.0001) of breast cancer patients. Conclusions: This is one of the first studies to show that a host factor in bone marrow confers prognostic importance. CD47 is an important biomarker in breast cancer, and functions as a prognostic factor for DFS. Moreover, we suggest that the poor prognosis of breast cancer patients with high expression of CD47 is due to an active CD47/SIRPA signaling pathway in circulating cells.

Original languageEnglish
Pages (from-to)4625-4635
Number of pages11
JournalClinical Cancer Research
Volume16
Issue number18
DOIs
Publication statusPublished - Sep 15 2010

Fingerprint

Bone Marrow
Breast Neoplasms
Recurrence
Disease-Free Survival
Survival
Multivariate Analysis
Messenger RNA
Real-Time Polymerase Chain Reaction
Research Design
Biomarkers
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. / Nagahara, Makoto; Mimori, Koshi; Kataoka, Akemi; Ishii, Hideshi; Tanaka, Fumiaki; Nakagawa, Tsuyoshi; Sato, Takanobu; Ono, Shinji; Sugihara, Kenichi; Mori, Masaki.

In: Clinical Cancer Research, Vol. 16, No. 18, 15.09.2010, p. 4625-4635.

Research output: Contribution to journalArticle

Nagahara, Makoto ; Mimori, Koshi ; Kataoka, Akemi ; Ishii, Hideshi ; Tanaka, Fumiaki ; Nakagawa, Tsuyoshi ; Sato, Takanobu ; Ono, Shinji ; Sugihara, Kenichi ; Mori, Masaki. / Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 18. pp. 4625-4635.
@article{e96b6c6c3d344873a2e7a32baf3b1f5a,
title = "Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients",
abstract = "Purpose: CD47 plays a variety of roles in intercellular signaling. Herein, we focused on the clinicopathologic significance of CD47 expression in human breast cancer. Our data suggest that the correlation between CD47 and signal regulatory protein α (SIRPA) expression may play a key role in the progression of breast cancer. Experimental Design: Quantitative real-time PCR was used to evaluate CD47 mRNA and SIRPA mRNA expression in bone marrow and in peripheral blood from 738 cases of breast cancer. Results: In patients with high levels of CD47 expression in the bone marrow, survival was significantly poorer compared with patients with low levels of CD47 expression [disease-free survival (DFS), P = 0.0035; overall survival (OS), P = 0.015]. Furthermore, high CD47 expression group in a multivariate analysis showed significance as an independent variable for poorer prognosis in DFS (P = 0.024). In the peripheral blood, however, high CD47 expression in patients was not an independent and significant prognostic factor for DFS and OS in a multivariate analysis. CD47 expression was strongly correlated with SIRPA expression in both the bone marrow (P < 0.0001) and peripheral blood (P < 0.0001) of breast cancer patients. Conclusions: This is one of the first studies to show that a host factor in bone marrow confers prognostic importance. CD47 is an important biomarker in breast cancer, and functions as a prognostic factor for DFS. Moreover, we suggest that the poor prognosis of breast cancer patients with high expression of CD47 is due to an active CD47/SIRPA signaling pathway in circulating cells.",
author = "Makoto Nagahara and Koshi Mimori and Akemi Kataoka and Hideshi Ishii and Fumiaki Tanaka and Tsuyoshi Nakagawa and Takanobu Sato and Shinji Ono and Kenichi Sugihara and Masaki Mori",
year = "2010",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-10-0349",
language = "English",
volume = "16",
pages = "4625--4635",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients

AU - Nagahara, Makoto

AU - Mimori, Koshi

AU - Kataoka, Akemi

AU - Ishii, Hideshi

AU - Tanaka, Fumiaki

AU - Nakagawa, Tsuyoshi

AU - Sato, Takanobu

AU - Ono, Shinji

AU - Sugihara, Kenichi

AU - Mori, Masaki

PY - 2010/9/15

Y1 - 2010/9/15

N2 - Purpose: CD47 plays a variety of roles in intercellular signaling. Herein, we focused on the clinicopathologic significance of CD47 expression in human breast cancer. Our data suggest that the correlation between CD47 and signal regulatory protein α (SIRPA) expression may play a key role in the progression of breast cancer. Experimental Design: Quantitative real-time PCR was used to evaluate CD47 mRNA and SIRPA mRNA expression in bone marrow and in peripheral blood from 738 cases of breast cancer. Results: In patients with high levels of CD47 expression in the bone marrow, survival was significantly poorer compared with patients with low levels of CD47 expression [disease-free survival (DFS), P = 0.0035; overall survival (OS), P = 0.015]. Furthermore, high CD47 expression group in a multivariate analysis showed significance as an independent variable for poorer prognosis in DFS (P = 0.024). In the peripheral blood, however, high CD47 expression in patients was not an independent and significant prognostic factor for DFS and OS in a multivariate analysis. CD47 expression was strongly correlated with SIRPA expression in both the bone marrow (P < 0.0001) and peripheral blood (P < 0.0001) of breast cancer patients. Conclusions: This is one of the first studies to show that a host factor in bone marrow confers prognostic importance. CD47 is an important biomarker in breast cancer, and functions as a prognostic factor for DFS. Moreover, we suggest that the poor prognosis of breast cancer patients with high expression of CD47 is due to an active CD47/SIRPA signaling pathway in circulating cells.

AB - Purpose: CD47 plays a variety of roles in intercellular signaling. Herein, we focused on the clinicopathologic significance of CD47 expression in human breast cancer. Our data suggest that the correlation between CD47 and signal regulatory protein α (SIRPA) expression may play a key role in the progression of breast cancer. Experimental Design: Quantitative real-time PCR was used to evaluate CD47 mRNA and SIRPA mRNA expression in bone marrow and in peripheral blood from 738 cases of breast cancer. Results: In patients with high levels of CD47 expression in the bone marrow, survival was significantly poorer compared with patients with low levels of CD47 expression [disease-free survival (DFS), P = 0.0035; overall survival (OS), P = 0.015]. Furthermore, high CD47 expression group in a multivariate analysis showed significance as an independent variable for poorer prognosis in DFS (P = 0.024). In the peripheral blood, however, high CD47 expression in patients was not an independent and significant prognostic factor for DFS and OS in a multivariate analysis. CD47 expression was strongly correlated with SIRPA expression in both the bone marrow (P < 0.0001) and peripheral blood (P < 0.0001) of breast cancer patients. Conclusions: This is one of the first studies to show that a host factor in bone marrow confers prognostic importance. CD47 is an important biomarker in breast cancer, and functions as a prognostic factor for DFS. Moreover, we suggest that the poor prognosis of breast cancer patients with high expression of CD47 is due to an active CD47/SIRPA signaling pathway in circulating cells.

UR - http://www.scopus.com/inward/record.url?scp=77956664396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956664396&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-0349

DO - 10.1158/1078-0432.CCR-10-0349

M3 - Article

C2 - 20705613

AN - SCOPUS:77956664396

VL - 16

SP - 4625

EP - 4635

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -